doxazosin has been researched along with Cardiac Failure in 40 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to evaluate the effect of carvedilol on nitrate tolerance in patients with chronic heart failure." | 9.08 | Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. ( Kakihana, M; Ohtsuka, S; Sugishita, Y; Watanabe, H, 1998) |
| "In this study we evaluated the effects of once-daily administration of oral doxazosin in patients with chronic congestive heart failure (CHF)." | 9.07 | Doxazosin for the treatment of chronic congestive heart failure: results of a randomized double-blind and placebo-controlled study. ( Chakko, S; DiBianco, R; Emmanuel, G; Marlon, A; Parker, JO; Singh, JB; Tanser, PH, 1991) |
| "Doxazosin treatment has been discouraged in hypertensive patients in order to prevent heart failure (HF) development." | 7.75 | Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients. ( Arioli, F; Cuko, A; Fragasso, G; Gardini, C; Margonato, A; Palloshi, A; Roccaforte, R; Salerno, A; Spoladore, R, 2009) |
| "Lower heart failure (HF) rates in individuals taking chlorthalidone vs amlodipine, lisinopril, or doxazosin were unanticipated in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)." | 5.14 | Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome? ( Barzilay, J; Cutler, JA; Dart, RA; Davis, BR; Graumlich, JF; Grimm, RH; Margolis, KL; Murden, RA; Piller, LB; Randall, OS, 2009) |
| " The double-blind, active-controlled component of ALLHAT was designed to determine whether the rate of the primary outcome-a composite of fatal coronary heart disease and nonfatal myocardial infarction-differs between diuretic (chlorthalidone) treatment and each of three other classes of antihypertensive drugs: a calcium antagonist (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin) in high-risk hypertensive persons ages 55 years and older." | 5.09 | Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Bettencourt, J; Davis, BR; Ford, CE; Furberg, CD; Geraci, TS; Kimmel, B; Kingry, C; Lusk, C; Nwachuku, C; Parks, H; Piller, LB; Pressel, SL; Simpson, LM; Wright, JT, 2001) |
| "This study was designed to evaluate the effect of carvedilol on nitrate tolerance in patients with chronic heart failure." | 5.08 | Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. ( Kakihana, M; Ohtsuka, S; Sugishita, Y; Watanabe, H, 1998) |
| "In this study we evaluated the effects of once-daily administration of oral doxazosin in patients with chronic congestive heart failure (CHF)." | 5.07 | Doxazosin for the treatment of chronic congestive heart failure: results of a randomized double-blind and placebo-controlled study. ( Chakko, S; DiBianco, R; Emmanuel, G; Marlon, A; Parker, JO; Singh, JB; Tanser, PH, 1991) |
| "Doxazosin treatment has been discouraged in hypertensive patients in order to prevent heart failure (HF) development." | 3.75 | Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients. ( Arioli, F; Cuko, A; Fragasso, G; Gardini, C; Margonato, A; Palloshi, A; Roccaforte, R; Salerno, A; Spoladore, R, 2009) |
| "ALLHAT, a randomized, double-blind, active-controlled hypertension treatment trial in 42,418 patients, reported that a thiazide-type diuretic (chlorthalidone) was superior to a calcium channel blocker (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), and an alpha1-blocker (doxazosin) in preventing the new onset of heart failure (HF)." | 3.74 | The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. ( Black, HR; Cushman, WC; Davis, BR; Einhorn, PT; Levy, D; Massie, BM; Nwachuku, CE; Piller, LB; Simpson, LM, 2007) |
| " To assess whether these differential structural effects do translate into different effects on LV function and on heart failure mortality, Bd or sham Bd 8-week-old rats were randomized to vehicle treatment (Vh), chemical sympathectomy ([Sx] 6-hydroxydopamine, 150 mg/kg IP twice a week), beta-adrenoceptor blockade (propranolol [Pro], 40 mg/kg per day PO), or alpha-adrenoceptor blockade (doxazosin [Dox], 5 mg/kg per day PO)." | 3.73 | Survival benefits of different antiadrenergic interventions in pressure overload left ventricular hypertrophy/failure. ( Busca, G; Cesana, F; Clari, F; Ferrari, AU; Ferrero, I; Gatti, C; Janetti, MB; Mancia, G; Palladini, G; Perlini, S; Tozzi, R; Vezzoli, M, 2006) |
| "Background Hypertension is a known risk factor for heart failure ( HF ), possibly via the mechanism of cardiac remodeling and left ventricular hypertrophy ( LVH )." | 2.90 | Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study. ( Davis, BR; Johnson, K; Oparil, S; Tereshchenko, LG, 2019) |
| "Hypertension is a major cause of heart failure (HF) and is antecedent in 91% of cases." | 2.72 | Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ( Colon, P; Crow, R; Cutler, JA; Davis, BR; Dunn, K; Ellsworth, A; Franklin, S; Furberg, C; Goff, D; Golden, J; Leenen, F; Mohiuddin, S; Papademetriou, V; Piller, LB; Proschan, M, 2006) |
| "The doxazosin arm was terminated early, when the trial's safety and monitoring board noted a twofold higher incidence of congestive heart failure in patients receiving doxazosin than in those receiving chlorthalidone (8." | 1.31 | Alpha-blockers and congestive heart failure: early termination of an arm of the ALLHAT trial. ( Vidt, DG, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.50) | 18.2507 |
| 2000's | 34 (85.00) | 29.6817 |
| 2010's | 3 (7.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Drzayich Antol, D | 1 |
| Waldman Casebeer, A | 1 |
| Khoury, R | 1 |
| Michael, T | 1 |
| Renda, A | 1 |
| Hopson, S | 1 |
| Parikh, A | 1 |
| Stein, A | 1 |
| Costantino, M | 1 |
| Stemkowski, S | 1 |
| Bunce, M | 1 |
| Nevo, N | 1 |
| Abu-Abeid, S | 1 |
| Hazzan, D | 1 |
| Lahat, G | 1 |
| Nachmani, I | 1 |
| Eldar, SM | 1 |
| Zhang, L | 1 |
| Xia, X | 1 |
| Zhong, Y | 1 |
| Xie, D | 1 |
| Liu, S | 1 |
| Wang, X | 1 |
| Tu, J | 1 |
| Faconti, L | 1 |
| Mills, CE | 1 |
| Govoni, V | 1 |
| Gu, H | 1 |
| Morant, S | 1 |
| Jiang, B | 1 |
| Cruickshank, JK | 1 |
| Webb, AJ | 1 |
| Lin, J | 1 |
| Wu, YJ | 1 |
| Liang, X | 1 |
| Ji, M | 1 |
| Ying, HM | 1 |
| Wang, XY | 1 |
| Sun, X | 1 |
| Shao, CH | 1 |
| Zhan, LX | 1 |
| Zhang, Y | 1 |
| Czamara, K | 1 |
| Karnas, E | 1 |
| Majka, Z | 1 |
| Wojcik, T | 1 |
| Zuba-Surma, EK | 1 |
| Baranska, M | 1 |
| Kaczor, A | 1 |
| Liu, X | 1 |
| Zhou, F | 1 |
| Yang, Y | 1 |
| Wang, W | 1 |
| Niu, L | 1 |
| Zuo, D | 1 |
| Li, X | 1 |
| Hua, H | 1 |
| Zhang, B | 1 |
| Kou, Y | 1 |
| Guo, J | 1 |
| Kong, F | 1 |
| Pan, W | 1 |
| Gao, D | 1 |
| Meves, JM | 1 |
| Sun, H | 1 |
| Xue, M | 1 |
| Zhang, Q | 1 |
| Wang, Y | 1 |
| Tang, R | 1 |
| Iso, T | 1 |
| Haruyama, H | 1 |
| Sunaga, H | 1 |
| Matsui, H | 1 |
| Matsui, M | 1 |
| Tanaka, R | 1 |
| Umbarawan, Y | 1 |
| Syamsunarno, MRAA | 1 |
| Putri, M | 1 |
| Yamaguchi, A | 1 |
| Hanaoka, H | 1 |
| Negishi, K | 1 |
| Yokoyama, T | 1 |
| Kurabayashi, M | 1 |
| Palomo-Briones, R | 1 |
| Esquivel-González, S | 1 |
| Aizpuru, A | 1 |
| Gómez-Hernández, N | 1 |
| Casas-Flores, S | 1 |
| Barba de la Rosa, AP | 1 |
| Arriaga, S | 1 |
| Peterson, ME | 1 |
| Carothers, MA | 1 |
| Gamble, DA | 1 |
| Rishniw, M | 1 |
| Johnson, K | 1 |
| Oparil, S | 1 |
| Davis, BR | 6 |
| Tereshchenko, LG | 1 |
| Kostis, JB | 1 |
| Simpson, LM | 3 |
| Black, HR | 2 |
| Cushman, WC | 2 |
| Einhorn, PT | 2 |
| Farber, MA | 1 |
| Ford, CE | 2 |
| Levy, D | 2 |
| Massie, BM | 2 |
| Nawaz, S | 1 |
| Barrios, V | 1 |
| Escobar, C | 1 |
| Tomás, JP | 1 |
| Calderon, A | 1 |
| Echarri, R | 1 |
| Spoladore, R | 1 |
| Roccaforte, R | 1 |
| Fragasso, G | 1 |
| Gardini, C | 1 |
| Palloshi, A | 1 |
| Cuko, A | 1 |
| Arioli, F | 1 |
| Salerno, A | 1 |
| Margonato, A | 1 |
| Grimm, RH | 1 |
| Piller, LB | 4 |
| Cutler, JA | 2 |
| Margolis, KL | 1 |
| Barzilay, J | 1 |
| Dart, RA | 1 |
| Graumlich, JF | 1 |
| Murden, RA | 1 |
| Randall, OS | 1 |
| Chapman, N | 1 |
| Chen, CY | 1 |
| Fujita, T | 1 |
| Hobbs, FD | 1 |
| Kim, SJ | 1 |
| Staessen, JA | 1 |
| Tanomsup, S | 1 |
| Wang, JG | 1 |
| Williams, B | 1 |
| Paran, E | 1 |
| Düsing, R | 1 |
| Lohm, L | 1 |
| Lindh, E | 1 |
| Frösing, R | 1 |
| Järhult, B | 2 |
| Lindahl, SO | 2 |
| Furberg, C | 2 |
| Gustafsson, LL | 1 |
| Cervera Casino, P | 1 |
| Ruiz García, V | 1 |
| Gervas Camacho, J | 1 |
| Kieback, AG | 1 |
| Rödiger, O | 1 |
| Jaenecke, H | 1 |
| Grohmann, A | 1 |
| Wernecke, KD | 1 |
| Baumann, G | 1 |
| Felix, SB | 1 |
| Dunn, K | 1 |
| Franklin, S | 1 |
| Goff, D | 1 |
| Leenen, F | 1 |
| Mohiuddin, S | 1 |
| Papademetriou, V | 1 |
| Proschan, M | 1 |
| Ellsworth, A | 1 |
| Golden, J | 1 |
| Colon, P | 1 |
| Crow, R | 1 |
| Yusuf, S | 1 |
| Perlini, S | 1 |
| Ferrero, I | 1 |
| Palladini, G | 1 |
| Tozzi, R | 1 |
| Gatti, C | 1 |
| Vezzoli, M | 1 |
| Cesana, F | 1 |
| Janetti, MB | 1 |
| Clari, F | 1 |
| Busca, G | 1 |
| Mancia, G | 1 |
| Ferrari, AU | 1 |
| Nwachuku, CE | 1 |
| Kukin, ML | 1 |
| Kalman, J | 1 |
| Mannino, M | 1 |
| Freudenberger, R | 1 |
| Buchholz, C | 1 |
| Ocampo, O | 1 |
| Watanabe, H | 1 |
| Kakihana, M | 1 |
| Ohtsuka, S | 1 |
| Sugishita, Y | 1 |
| SoRelle, R | 1 |
| Messerli, FH | 3 |
| Ball, SG | 1 |
| Thackray, S | 1 |
| Witte, K | 1 |
| Clark, AL | 1 |
| Cleland, JG | 1 |
| Vidt, DG | 1 |
| Grossman, E | 1 |
| Hansson, L | 1 |
| Feldman, RD | 1 |
| Campbell, N | 1 |
| Larochelle, P | 1 |
| Osnes, JB | 1 |
| Aass, H | 1 |
| Andersen, GO | 1 |
| Skomedal, T | 1 |
| Pressel, SL | 1 |
| Wright, JT | 1 |
| Geraci, TS | 1 |
| Kingry, C | 1 |
| Bettencourt, J | 1 |
| Kimmel, B | 1 |
| Lusk, C | 1 |
| Parks, H | 1 |
| Nwachuku, C | 1 |
| Furberg, CD | 1 |
| McLellan, F | 1 |
| Faulhaber, HD | 1 |
| Simon, HB | 1 |
| Kjeldsen, SE | 1 |
| DiBianco, R | 1 |
| Parker, JO | 1 |
| Chakko, S | 1 |
| Tanser, PH | 1 |
| Emmanuel, G | 1 |
| Singh, JB | 1 |
| Marlon, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for doxazosin and Cardiac Failure
| Article | Year |
|---|---|
Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension?
Topics: Adrenergic alpha-1 Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Clinical Trials as | 2010 |
Doxazosin and congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adverse Drug Reaction Reporting Systems; Angiotensin-Converting Enzyme | 2001 |
13 trials available for doxazosin and Cardiac Failure
| Article | Year |
|---|---|
Topics: Adult; Aged; Animals; Astrocytes; Bariatric Surgery; Beta vulgaris; Bioreactors; Biotechnology; Bloo | 2018 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Antihypertensive Agents; Coronary Disease; Double-Bl | 2008 |
Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome?
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Confidence Intervals; Double-Blind Meth | 2009 |
Hemodynamic effects of alpha1-adrenoceptor antagonist, doxazosin, in patients with chronic congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Aged; Chronic Disease; Double-Blind Method; Doxazosin; Electrocardiogr | 2005 |
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2006 |
Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta blockade alone in chronic congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Chronic Disease; Doxazosin; | 1996 |
Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure.
Topics: Adrenergic Antagonists; Aged; Blood Flow Velocity; Blood Platelets; Blood Pressure; Carbazoles; Carv | 1998 |
National Heart, Lung, and Blood Institute halts part of antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Topics: Adrenergic alpha-Antagonists; Anticholesteremic Agents; Chlorthalidone; Diuretics; Doxazosin; Female | 2000 |
Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adverse Drug Reaction Reporting Systems; Anticholesteremic Agents; Antihypertensive Agents; Chlortha | 2000 |
Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme | 2000 |
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adverse Drug Reaction Reporting Systems; Antihypertensive Agents; Cause of Death; Coronary Disease; | 2001 |
Doxazosin for the treatment of chronic congestive heart failure: results of a randomized double-blind and placebo-controlled study.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Doxazosin; Exercise; Female; Heart Failure; Hemod | 1991 |
25 other studies available for doxazosin and Cardiac Failure
| Article | Year |
|---|---|
Doxazosin and heart failure: to be or not to be.
Topics: Antihypertensive Agents; Doxazosin; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricul | 2009 |
Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients.
Topics: Aged; Antihypertensive Agents; Doxazosin; Female; Heart Failure; Hospitalization; Humans; Hypertensi | 2009 |
Doxazosin and ALLHAT trial: a response.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Doxazos | 2002 |
[The new (old) knowledge in primary prevention of stroke. It depends on lowering of blood pressure].
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2003 |
[Alfadil and heart failure--clinical conclusions do exist!].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Doxazosin; Drug Information Services; Heart Failu | 2003 |
[Doxazosin and heart failure: truthful information--for the sake of patients].
Topics: Antihypertensive Agents; Doxazosin; Drug Information Services; Heart Failure; Humans | 2003 |
[Doxazosin and heart failure: a clinical conclusion is wanted].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Doxazosin; Heart Failure; Humans; Hypertensio | 2003 |
[Alfadil--positive documentation when it comes to safety is missing].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Documentation; Doxazosin; Drug Information Se | 2003 |
[Choice of antihypertensive agent--insignificant role of doxazosin (Alfadil). How are evidence-based recommendations implemented?].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Contraindications; Doxazosin; Evidence-Based | 2004 |
[Antihypertensive therapy and congestive heart failure].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Doxazosin; Drug Utilization; Heart Failure; H | 2005 |
Preventing vascular events due to elevated blood pressure.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Comorbidity; Doxazosin; Drug Thera | 2006 |
Survival benefits of different antiadrenergic interventions in pressure overload left ventricular hypertrophy/failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Aorta, Abdominal; Blood Pressure | 2006 |
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2007 |
Discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Heart Failure; Humans | 2000 |
Diuretics vs. alpha blockers.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Ca | 2000 |
Alpha-blockers and congestive heart failure: early termination of an arm of the ALLHAT trial.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Chlorthalidone; Doxazosin; Female; Heart Fail | 2000 |
Doxazosin arm of the ALLHAT study discontinued: how equal are antihypertensive drugs? Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2000 |
First-line antihypertensive therapy.
Topics: Antihypertensive Agents; Doxazosin; Heart Failure; Humans; Myocardial Infarction; Randomized Control | 2000 |
First-line antihypertensive therapy. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Doxazosin; Heart Failure; Humans; Randomized | 2000 |
First-line antihypertensive therapy.
Topics: Antihypertensive Agents; Chlorthalidone; Doxazosin; Heart Failure; Humans; Myocardium; Randomized Co | 2000 |
US FDA weighs options for warning on antihypertensive drug.
Topics: Antihypertensive Agents; Doxazosin; Drug Labeling; Heart Failure; Humans; United States; United Stat | 2001 |
[Alpha-blockers in therapy of arterial hypertension. No longer the drug of first choice].
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Cause of Death; Chlorthalidone; Doxazos | 2001 |
On call. I'm a 76-year-old man with an enlarged prostate. I've been taking Cardura and it's helped a lot, but my doctor stopped it because he said a study found the drug could cause heart failure. Now I'm getting up three or four times a night again. Is C
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Doxazosin; Heart Failure; Humans; Hyper | 2001 |
Heart lines. Cardura update.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Diuretics; Doxazosin; Heart Failure; Humans; | 2001 |
Warning for antihypertensive drug?
Topics: Antihypertensive Agents; Clinical Trials as Topic; Doxazosin; Drug Labeling; Heart Failure; Humans; | 2001 |